Every Form 4 that MAIA Biotechnology, Inc. (MAIA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MAIA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MAIA filings page.
MAIA Biotechnology director reports insider share purchases. Director Stan V. Smith filed a Form 4 showing two open-market purchases of MAIA common stock. On 11/24/2025, he bought 10,000 shares at a weighted average price of $0.99, with individual trades ranging from $0.9675 to $0.9899. On 11/25/2025, he bought another 15,000 shares at a weighted average price of $0.98, with trades between $0.9550 and $1.05. Following these transactions, he beneficially owns 1,349,289 shares indirectly through The Stan V. Smith Trust Dated 1993.
MAIA Biotechnology CEO share purchases were reported by Vlad Vitoc, who serves as Chief Executive Officer, Director and 10% owner of MAIA Biotechnology, Inc. (MAIA). On 11/21/2025, he bought 1,800 shares of common stock at a weighted average price of $0.92 per share, and on 11/24/2025 he bought an additional 10,000 shares at a price of $0.9891 per share.
Following these transactions, Vitoc directly beneficially owned 820,921 shares of MAIA common stock. The filing also notes 210,100 shares beneficially owned by his spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest. The weighted average disclosure indicates the 1,800-share purchase was executed in multiple trades within a narrow price range between $0.9128 and $0.9235.